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Background: Misplacement during percutaneous aortic valve implantation can be
associated with severe complications. The DFM valve is repositionable and retrievable,
however, the non metallic inflatable and conformable design of the valve results in
less radial force which may have an impact on stability and valve function over time.
We therefore analyzed the mid-term stability of the position, shape and hemodynamic
performance of the Direct Flow Medical (DFM) percutaneous aortic valve.
Methods: Sixteen symptomatic high-risk for surgery patients (pts) with aortic stenosis
and a logistic Euroscore > 20 were implanted and the subject of this analysis. Clinical,
echocardiographic and Dual Source Multislice Computed Tomography (DSMCT) were
obtained during 2 year follow up.
Results: The 1- and 2- year survival rates were 81.3 and 68.7%, respectively. DSMCT
follow up indicated no changes in position, diameter, and orifice area of the DFM valve
over time. Echocardiography revealed a significant decrease of the mean gradient from
baseline (50.1±11.3 mmHg) to 30 days (19.6±5.7 mmHg, p < 0.001) which remained
stable over 2 years. The aortic valve area increased from 0.57 ± 0.15 cm2 at baseline
to 1.47 ± 0.35 cm2 at 30 days (p < 0.001) and did not significantly change during 2
year follow-up. 73% of pts had no aortic regurgitation, 27 % had minimal paravalvular
aortic regurgitation.
Conclusion: Two year follow up data of the nonmetallic, repositionable and retrievable
DFM valve show stability of the position, shape and hemodynamic performance with
no paravalvular aortic regurgitation in the majority of patients.
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Does Left Atrial Diameter in Patients with Severe Aortic Stenosis Have a
Clinical Impact on Outcome?
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Maluenda, Israel M Barbash, Manuel A Gonzalez, Michael A Gaglia, Rebecca
Torguson, William O Suddath, Lowell F Satler, Kenneth M Kent, Joseph M Lindsay,
Augusto D Pichard, Ron Waksman
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Background: Left atrium diameter (LAD) is an independent predictor for
cardiovascular events in patients with dilated or hypertrophic cardiomyopathy. This
study was undertaken to investigate the relationship among an abnormal LAD, aortic
valve area, clinical events, and the impact of aortic valve replacement on LAD in a
population with severe aortic stenosis (AS).
Methods: We investigated 530 patients with severe AS. Each patient underwent a TTE
with a standardized measurement of the LAD. Patients with moderate or severe mitral
regurgitation were excluded. Patients were divided into 3 groups based on their LAD.
Group I: LAD <4cm (n=124; 24%), group II: LAD 4-4,9cm (n=278; 52%) and group
III: LAD >5cm (n=128, 24%).
Results: Patients with an abnormal LAD (group III) had a higher incidence of heart
failure, including higher rate of BNP, pulmonary hypertension and a significant lower
ejection fraction. (Table 1) Atrial fibrillation was documented in 49.2% in group III as
compared to 20.3% and 27.9% in groups I and II, respectively with p <0.001. No
significant differences were found regarding the aortic valve area among the 3 groups
(p=0.430). LAD had moderate correlation with ejection fraction (r=-0.2, p <0.001),
pulmonary pressure (r=0.23, p <0.001) and with pulmonary capillary wedge pressure
(r=0.31, p <0.001). There was no correlation between LAD and aortic valve area (r=-
0.03, p= 0.48). There was no significant difference in mortality among the three groups.
(Figure 1) There was no significant reduction in LAD for any of the groups after T-
AVR: 5.21cm±0.6 vs. 5.23cm±0.57, p=0.75 and surgical AVR: 5.34cm±0.39
vs.5.37cm±0.98, p=0.97.
Conclusion: The treatment of aortic stenosis either by T-AVR or surgical AVR does
not reduce the LAD immediately post procedure. Large LAD in patients with severe
aortic stenosis is associated with heart failure and arrhythmia but not with the severity
of the aortic stenosis.
TCT-741
Candidates for Transcatheter Aortic Valve Replacement (TAVR): Fitting the
Current PARTNERS Criteria?
Michael John Babcock, Luis Guzman, Steven Lavine, Joel Strom, Theodore Bass
Cardiology, University of Florida at Jacksonville, Jacksonville, FL
Background: Transcatheter Aortic Valve Replacement (TAVR)may offer advanced
therapeutic options to patients with symptomatic aortic stenosis. After the publication
of PARTNERS cohort B, there is a growing interest in TAVR within institutions.
Societies recommended that an annual volume of 24 cases would be considered
reasonable and greater than 50 would be ideal. The aim of this study was to determine
from a tertiary care academic referral center, the volume of symptomatic aortic stenosis
(AS) patients fulfilling the PARTNERS B criteria.
Methods: Between 1/2008 and 12/2010, 33,543 echocardiograms in 21,652 patients
were retrospectively evaluated. Patients with any grade AS as graded in the final echo
report were identified and stratified by severity. Manual inpatient and outpatient chart
audits were performed to evaluate the presence of symptoms, specifically syncope,
angina or dyspnea consistent with NYHA class II congestive heart failure. Nonsurgical
candidates were evaluated for demographics, STS and Euroscore, and cross referenced
with the PARTNER cohort B exclusion criteria to determine potential eligibility for
TAVR.
Results: AS was identified in 833 patients (3.8%). Among them, moderate to severe
and severe AS was present in 192 patients (23%) of which 146 were symptomatic
(76%), with 65% considered surgical candidates. The average age in the nonsurgical
group was 81 years, 42% male, 48% diabetic, mean creatinine of 1.7, STS risk of
mortality of 7.9% + 6.2%, morbidity and mortality of 33.8% + 13.3% and logistic
Euroscore of 11.06% + 3%. Among the nonsurgical, after exclusions, only 15% met
PARTNERS criteria. (Figure).
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Conclusion: From a large echo database, symptomatic AS was identified in 0.7% of
patients. The majority of them are either surgical candidates or are excluded by the
current PARTNERS criteria. Only 15% of all severe symptomatic AS patients qualified
for TAVR. This information will be important for institutions considering
implementation of TAVR programs to meet minimal recommended volumes.
TCT-742
Finite Element Analysis of Transcatheter Aortic Valve Implantation: Impact of
Oversizing on Stent and Leaflet Stresses
Ali Azadani1, 2, Sam Chitsaz1, 2, Elaine Tseng1, 2, Liang Ge1, 2
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Background: Transcatheter aortic valve implantation (TAVI) has emerged as an
alternative treatment for high risk surgical patients with severe symptomatic aortic
stenosis. Transcatheter aortic valves (TAVs) are implanted in a sutureless fashion using
oversizing to achieve appropriate anchoring and reduce paravalvular leak. Optimal
TAV function requires expansion of the valve to its nominal dimensions. However,
incomplete and non-uniform expansion of TAV was observed in the majority of
patients. Under-expanded TAVs are expected to function suboptimally which may
impact long-term durability. Stress analysis of leaflets and stent after TAVI has not
been studied.
Methods: A computer aided design (CAD) model of a balloon-expandable TAV was
developed based on the 23mm Edwards-SAPIEN valve design and used to create a
finite element (FE) model. The 3D model consists of a stent, three pericardial leaflets,
a clamp compression unit and an expandable balloon. Large deformation FE
simulations were conducted to model TAV crimping and balloon-expansion to 17, 21,
and 23mm.
Results: Stress distribution on the stent and leaflets are shown in Figure 1. As post-
inflation diameter increased, von Mises stress on the TAV stent decreased. Maximum
von Mises stresses on the stent after expansion to 17, 21, and 23mm were 365, 346,
and 262 MPa, respectively. Unlike the stent, the leaflet stress increased as the post-
inflation diameter increased.
Figure 1. Von Mises stress distribution on TAV stent (top) and leaflets (bottom) after
balloon-expansion to 17 and 21mm.
Conclusion: A FE model was developed to model crimping and balloon expansion of
TAVI. Stress on stent and leaflets after implantation was dependent on the internal
diameter of the inflated stent. FE modeling can be used to predict post-TAVI stresses
and evaluate whether a specific TAV size and design is optimal for a specific patient.
TCT-743
Incidence, timing and predictors of valve dislodgment during TAVI with the
Medtronic Corevalve System
Nicolas M Van Mieghem, Carl J Schultz, Robert M van der Boon, Rutger-Jan Nuis,
Apostolos Tzikas, Marcel L Geleijnse, Ron T van Domburg, Patrick W Serruys, Peter
P de Jaegere
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Background: Periprocedural valve dislodgment may occur during transcatheter aortic
valve implantation (TAVI). The aim of this study was to determine the incidence,
timing and predictors of periprocedural valve dislodgment with the Medtronic
Corevalve System (MCS).
Methods: Ninety-eight consecutive patients underwent TAVI with the MCS after a
comprehensive baseline assessment including invasive angiography, echocardiography
and Multi-Slice Computed Tomography (MSCT). The invasive monitoring charts and
angiographic studies of all TAVI procedures were reviewed to determine the incidence
and timing of valve dislodgment.
Results: Valve dislodgment occurred in 18 patients. Patients with valve dislodgment
had a larger Aortic Valve Area (0.76 ± 0.25 cm2 vs. 0.61 ± 0.19 cm2, p = 0.007), lower
mean transaortic gradient (37.65 ± 14.62 mmHg vs. 47.11 ± 16.08 mmHg, p = 0.03)
and significantly less aortic root calcification (Agatston score median 1951 AU (IQR
799 – 3103) vs 3289 AU (IQR 2097 – 4481), p = 0.016). A lower aortic root calcium
score (Agatston score < 2359 AU) was the single independent predictor for valve
dislodgment (OR 3.10, 1.09 – 8.84). After valve dislodgment, the valve could be
successfully retrieved and implanted in the proper anatomic location in all cases. Valve
dislodgment was associated with a lower incidence of post-procedural AR ≥ 2 (11.1%
vs 34.6%, p = 0.05). There were no relevant procedural or clinical implications to valve
dislodgment.
Conclusion: The incidence of periprocedural valve dislodgment was 18% in these
series. Less aortic root calcification appeared the single independent predictor.
TCT-744
Edwards-SAPIEN Valve Positioning during Transcatheter Aortic-Valve
Implantation: Multicenter Evaluation with Clinical and Anatomical Correlates
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Background: Accurate valve positioning during transcatheter aortic-valve
implantation is crucial in order to achieve optimal results. Our objectives were to
evaluate the exact location of the Edwards-SAPIEN valve in different stages of
implantation and to analyze possible operator-independent movement of the valve
during final deployment.
Methods: We used the C-THV system (Paieon Medical), for evaluating Edwards-
SAPIEN procedures from 4 medical centers. Valve position was analyzed in relation
to the native valve annulus (virtual target line) in several stages during the procedure
and defined as the fraction (%) of valve below the target-line, into the left-ventricle
outflow tract, in relation to the total prosthetic valve height.
Results: The study group consisted of 68 patients; age 82.9±8 years. The proportion
of the valve located below the target line was as follows: before aortic contrast
injection, 37.3±16.1%; after injection, 39±13.1%; during rapid pacing, 32.6±13.8%;
after implantation, 16.7±16.3%. The final location of the implanted valve was
significantly higher than in the other stages of the procedure (p<0.0001). In 91.2% of
cases, final valve location was less than 40% below the target-line. Operator-
independent valve movement toward the aorta occurred between the rapid pacing and
final valve location stages (mean 2±1.43 mm upward movement of valve center, range
-1.3 to 4.6). Multivariate analysis revealed that this movement was independent of
valve version (SAPIEN 2.12±1.32 mm vs. SAPIEN-XT1.87±1.55 mm, p=0.49), valve
size (23 mm 2.13±1.21 mm vs. 26 mm 1.83±1.7 mm, p=0.2), or procedural access
(trans-femoral 1.78±1.41 mm vs. trans-apical 2.39±1.43 mm, p=0.11). This upward
movement was asymmetrical, occurring mainly in the lower part of the valve (3.2±1.4
mm vs. 0.75±1.5 mm for upper part, p<0.001), resulting in valve shortening.
Moderate/severe aortic-valve calcification was associated with a higher upward
movement of the lower valve part than mild calcification (3.8±1.4 mm vs. 2.7±1.6 mm,
p=0.017).
Conclusion: During Edwards-SAPIEN implantation, final valve position seems to be
higher (i.e. towards the aorta) than planned by the operators. Apparently, there is an
operator-independent upward movement of the valve during the final stage of
implantation and possibly asymmetric shortening of the valve, especially in highly
calcified valves.
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